Advancing Cancer Treatment
Therapeutics Discovery
Tim Heffernan, Ph.D.
Vice President and Division Head
The Therapeutics Discovery division at MD Anderson works with unparalleled proximity to patients and an unmatched wealth of clinical expertise to eliminate the bottlenecks that hamper traditional drug development, allowing us to benefit more patients to a greater degree.
We work across all classes of therapeutics, including small molecule drugs, biologics and cellular therapies, to effectively address unmet needs in oncology. Our dedicated team of scientists, clinicians, drug developers and data experts develops new therapies inspired by the needs of MD Anderson cancer patients and guided by the expertise of the institution’s world-renowned physicians.
Therapeutics Discovery doesn’t bring the “bench to bedside” — it starts with the bench at the bedside — with each patient and their cancer.
Therapeutics Pipeline
We have leveraged our unique approach to discover and advance novel therapies to answer unmet needs that will improve the lives of our patients.
Learn more about our pipelineIn the News
Stay up to date on our new collaborations and recent progress.
MD Anderson and Sibylla Biotech announce...
The University of Texas MD Anderson Cancer Center and Sibylla Biotech today announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as folding interfering degraders (FIDs), which disrupt the proper folding of target proteins and lead to their degradation.
Under the agreement, Sibylla and MD Anderson will jointly conduct discovery and development work from target identification...
MD Anderson and CureVac enter strategic...
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical...
Our Unique Model
We are a drug development engine joining industry-scale capabilities with the clinical and research expertise of MD Anderson. Our experienced teams rapidly advance new therapies across all modalities. We also collaborate with leading biopharmaceutical companies to bring new medicines to patients in need.
Learn more about our approach